See every side of every news story
Get Started
SubscribeLogin
Basketball
Donald Trump
CPAC
Everton
Pope Francis
Hamas
Ukraine War
Volodymyr Zelenskyy
Baseball
Elon Musk
Israel-Hamas Conflict
Premier League
Published • loading... • Updated

HIMS stock crashes 25% on Friday after this key FDA update

Summary by Invezz
Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01. The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk’s weight-loss drugs.Despite this setback, HIMS stock had surged 43% in the past five days leading up to the FDA’s announcement, making today’s sharp drop a reversal of those recent gains.HIMS stock was down around 21% to trade…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
abbonews.comabbonews.com

Hims & Hers Health Stock Plummets as FDA Ends Novo Nordisk Drug Shortage

Shares of Hims & Hers Health (NYSE: HIMS) plunged 23% on Friday after the U.S. Food and Drug Administration (FDA) announced that the shortage of Novo Nordisk

Read Full Article
InvezzInvezz

HIMS stock crashes 25% on Friday after this key FDA update

Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01. The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk’s weight-loss drugs.Despite this setback, HIMS stock had surged 43% in the past five days leading up to the FDA’s announcement, making today’s sharp drop a reversal of those recent gains.HIMS stock was down around 21% to trade…

Read Full Article
Wall Street PitWall Street Pit

Hims & Hers Crashes as FDA Ends Semaglutide Shortage - Wall Street Pit

Hims & Hers Health (HIMS) shares  are nosediving in early trading, down 21% to $53.32, after the FDA declared the semaglutide shortage resolved, threatening the company’s profitable sales of compounded GLP-1 weight-loss drugs. The FDA’s confirmation of adequate supply from manufacturers like Novo Nordisk eliminates the regulatory basis for Hims…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Wall Street Pit broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)

Similar News Topics

Stock Markets

Stock Markets

United States

United States

US Economy

US Economy

News
For You
Search
BlindspotLocal